Department of Infertility and Reproductive Medicine, Istanbul German Hospital, Istanbul, Turkey.
Gynecol Endocrinol. 2010 Jul;26(7):505-8. doi: 10.3109/09513591003632233.
We retrospectively assessed outcomes of in vitro fertilisation in groups of women with asymptomatic incidentally discovered hyperprolactinaemia (AIH) undergoing ovarian stimulation and ICSI-ET relative to the types of dopamine agonist and gonadotropin releasing hormone analogue used. Of 5840 women who underwent COH and ICSI-ET, 239 were included in the study; 122 had been treated with cabergoline, and 117 with bromocriptine, during the COH. The mean age, duration of stimulation, and total number of gonadotropin ampules employed were comparable in the two groups using the agonist and antagonist protocols, as were the number of oocytes retrieved and the proportion of mature MII and fertilised (2pn) oocytes. There were no significant differences in implantation, pregnancy, and miscarriage rates between the agonist and antagonist arms of the study. The cost of treatment was significantly higher with cabergoline than with bromocriptine (p = 0.0001). However, side effect rate was significantly higher with bromocriptine than with cabergoline (15.3% vs. 2.5%; p = 0.0004). In conclusion, we found that cabergoline and bromocriptine showed no differences in IVF outcomes and pregnancy results in patients with AIH.
我们回顾性评估了在接受卵巢刺激和 ICSI-ET 的无症状偶发性高泌乳素血症（AIH）女性中，使用不同类型的多巴胺激动剂和促性腺激素释放激素类似物的体外受精结局。在接受 COH 和 ICSI-ET 的 5840 名女性中，有 239 名女性纳入了本研究；其中 122 名在 COH 期间接受了卡麦角林治疗，117 名接受了溴隐亭治疗。在使用激动剂和拮抗剂方案时，两组的平均年龄、刺激持续时间和促性腺激素安瓿总数、采集的卵母细胞数量以及成熟 MII 和受精（2pn）卵母细胞的比例相当。在研究的激动剂和拮抗剂组之间，胚胎着床率、妊娠率和流产率没有显著差异。卡麦角林的治疗费用明显高于溴隐亭（p = 0.0001）。然而，溴隐亭的副作用发生率明显高于卡麦角林（15.3%比 2.5%；p = 0.0004）。总之，我们发现卡麦角林和溴隐亭在 AIH 患者的 IVF 结局和妊娠结果方面没有差异。
